These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 28595520

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy.
    Okamoto M, Okamoto M, Gotoh K, Masaki T, Ozeki Y, Ando H, Anai M, Sato A, Yoshida Y, Ueda S, Kakuma T, Shibata H.
    J Diabetes Investig; 2016 Nov; 7(6):915-918. PubMed ID: 27181090
    [Abstract] [Full Text] [Related]

  • 24. Millennium award recipient contribution. Identification of children with early onset and high incidence of anti-islet autoantibodies.
    Robles DT, Eisenbarth GS, Wang T, Erlich HA, Bugawan TL, Babu SR, Barriga K, Norris JM, Hoffman M, Klingensmith G, Yu L, Rewers M, Diabetes Autoimmunity Study in the Young.
    Clin Immunol; 2002 Mar; 102(3):217-24. PubMed ID: 11890708
    [Abstract] [Full Text] [Related]

  • 25. Non-transmitted maternal HLA DQ2 or DQ8 alleles and risk of Type I diabetes in offspring: the importance of foetal or post partum exposure to diabetogenic molecules.
    Pani MA, Van Autreve J, Van der Auwera BJ, Gorus FK, Badenhoop K.
    Diabetologia; 2002 Sep; 45(9):1340-3. PubMed ID: 12242468
    [Abstract] [Full Text] [Related]

  • 26. Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab.
    Sakurai K, Niitsuma S, Sato R, Takahashi K, Arihara Z.
    Tohoku J Exp Med; 2018 Jan; 244(1):33-40. PubMed ID: 29343652
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
    Wen L, Zou X, Chen Y, Bai X, Liang T.
    Front Immunol; 2020 Jan; 11():2076. PubMed ID: 32973816
    [Abstract] [Full Text] [Related]

  • 31. HLA-DR genotypes influence age at disease onset in children and juveniles with type 1 diabetes mellitus.
    Awa WL, Boehm BO, Kapellen T, Rami B, Rupprath P, Marg W, Becker M, Holl RW, DPV-Wiss Study Group and the German Competence Network Diabetes Mellitus.
    Eur J Endocrinol; 2010 Jul; 163(1):97-104. PubMed ID: 20371654
    [Abstract] [Full Text] [Related]

  • 32. Genetic susceptibility to type 1 diabetes: clinical and molecular heterogeneity of IDDM1 and IDDM12 in a german population.
    Badenhoop K, Donner H, Pani M, Rau H, Siegmund T, Braun J.
    Exp Clin Endocrinol Diabetes; 1999 Jul; 107 Suppl 3():S89-92. PubMed ID: 10522814
    [Abstract] [Full Text] [Related]

  • 33. Genetic risk markers related to diabetes-associated autoantibodies in young patients with type 1 diabetes in berlin, Germany.
    Kordonouri O, Hartmann R, Charpentier N, Knip M, Danne T, Ilonen J.
    Exp Clin Endocrinol Diabetes; 2010 Apr; 118(4):245-9. PubMed ID: 20140847
    [Abstract] [Full Text] [Related]

  • 34. HLA DR phenotypic frequencies and genetic risk of Type 1 diabetes in west region of Algeria, Tlemcen.
    Aribi M, Moulessehoul S, Benabadji AB, Kendoucitani M.
    BMC Genet; 2004 Aug 24; 5():24. PubMed ID: 15331022
    [Abstract] [Full Text] [Related]

  • 35. Autoantibodies in type 1 diabetes.
    Taplin CE, Barker JM.
    Autoimmunity; 2008 Feb 24; 41(1):11-8. PubMed ID: 18176860
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Anti-PD-1 and Anti-PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes.
    Mellati M, Eaton KD, Brooks-Worrell BM, Hagopian WA, Martins R, Palmer JP, Hirsch IB.
    Diabetes Care; 2015 Sep 24; 38(9):e137-8. PubMed ID: 26116720
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Intrinsic insulin secretion capacity might be preserved by discontinuing anti-programmed cell death protein 1 antibody treatment in 'anti-programmed cell death protein 1 antibody-induced' fulminant type 1 diabetes.
    Sakai G, Saito D, Nakajima R, Hatano M, Noguchi Y, Kurihara S, Katayama S, Inoue I, Noda M, Shimada A.
    J Diabetes Investig; 2018 Mar 24; 9(2):448-449. PubMed ID: 29504279
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.